Clinical Trial Update: Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 multicenter trial evaluating intravenous OvaRex MAb-B43.13 as post-chemotherapy consolidation in ovarian cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• OvaRex MAb-B43.13 (MAb-B43.13)

Snippet

Sponsor: Unither Pharmaceuticals | Conditions: Ovarian Neoplasms | Phase 2 | Status: TERMINATED